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Abstract
The management of severe intra-abdominal infections
remains a major challenge facing surgeons and inten-
sive  care  physicians,  because  of  its  association  with
high  morbidity  and  mortality.  surgical  management
and intensive care medicine have constantly improved,
but in the recent years a rapidly continuing emergence
of  resistant  pathogens  led  to  treatment  failure  sec-
ondary to infections with multi-drug resistant bacteria.
In secondary peritonitis the rate of resistant germs at
the initial operation is already 30 %. The lack of effec-
tive antibiotics against these pathogens resulted in the
development of new broad-spectrum compounds and
antibiotics directed against resistant germs. but so far
no “super-drug” with efficacy against all resistant bac-
teria exists. Even more, soon after their approval, re-
ports  on  resistance  against  these  novel  drugs  have
been reported, or the drugs were withdrawn from the
market due to severe side effects. since pharmaceutical
companies  reduced  their  investigations  on  antibiotic
research,  only  few  new  antimicrobial  derivates  are
available. 
In abdominal surgery you may be in fear that in the
future more and more patients with tertiary peritonitis
secondary to multi-drug resistant species are seen with
an increase of mortality after secondary peritonitis.
This article reviews the current treatment modali-
ties  for  complicated  intra-abdominal  infections  with
special reference to the antibiotic treatment of com-
plicated intra-abdominal infections with multi-drug re-
sistant species.
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Abbreviations:
cIaI Complicated intra-abdominal infection
Esbl Extended spectrum ￟-lactamase
IaI Intra-abdominal infection
ICu Intensive care unit




VRE Vancomycin resistant Enterococcus
HIsToRICal baCkgRound
one-hundred years ago complicated intra-abdominal
infections (cIaIs) were associated with mortality rates
of 90% [1]. during the last century more aggressive
surgical methods, intensive care management and the
availability of a large diversity of differently acting an-
tibiotics have reduced mortality below 25 % [2]. but at
the end of the first decade of the 21st century cIaIs
remain responsible for 20 % of severe sepsis in inten-
sive care units (ICu). Thus cIaIs represent the second
common cause for infectious morbidity and mortality
after pneumonia [3, 4].
The  treatment  of  cIaI  is  based  on  a  few  simple
principles,  including  focus  elimination,  lavage  con-
cepts, intensive care medicine and application of an-
tibiotics [5]. While innovative surgical techniques and
intensive care management constantly improved treat-
ment modalities for critical ill patients, the develop-
ment of new potent antibiotics was unable to follow
the rapidly increasing number of resistant germs [6-8].
To  assure  the  high  quality  in  the  management  of
cIaIs, surgeons will need substantial help of new an-
timicrobial compounds.
ClassIfICaTIon
Complicated intra-abdominal infections are usually de-
fined as abscess formation or peritonitis beyond the
origin of the perforation of a hollow viscus into the
peritoneal cavity, requiring an invasive procedure for
source control [9]. although the term intra-abdominal
infection (IaI) is often synonymously used with the
term peritonitis, there is a wide variation in the severi-
ty  of  illness  for  the  different  forms  and  origins  of
peritonitis. The mortality for patients with appendicitis
ranges between 5 % and 9 %, while the mortality for
gastric ulcer perforation is 21 % and ranges from 45 %
to 50 % for large bowel perforation or peritonitis orig-
inating from the biliary tract [1, 10, 11].
Peritonitis includes the local reaction of the organ
“peritoneum” and the patients’ systemic inflammatory
response to micro-organisms and their toxins. Thus,
peritonitis needs a clear differentiation from bacterial
contamination,  e.g.  in  acute  cholecystitis  or  gan-
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3 Uhl##_Umbruchvorlage  23.11.10  11:53  Seite 525grenous appendicitis, where local spillage of bacteria
into the abdominal cavity occurs, but infection is not
established.
usually  peritonitis  is  classified  into  primary,  sec-
ondary  (sP)  and  tertiary  peritonitis  (TP);  (Table  1,
forms of peritonitis) [12]. Primary peritonitis, also re-
ferred to as spontaneous peritonitis, arises without de-
rangement of anatomical barriers and has a low inci-
dence on surgical wards.
The most frequent entity is sP, which is defined as
infection of the peritoneal cavity resulting from perfo-
ration,  breakdown  of  an  intestinal  anastomosis,  is-
chemic necrosis or other injuries of the gastro-intesti-
nal tract [12]. according to the mode of acquisition
sP  is  divided  into  community-acquired  and  hospital
associated infections. Community-acquired peritonitis
is associated with bacterial stains originating from the
source of the infection, although today community ac-
quired infections with resistant species are a common
and serious problem [13]. usually patients with health
care associated peritonitis have a higher probability of
infections  with  opportunistic  nosocomial  facultative
pathogenic bacteria and fungi. The diversity of differ-
ent micro-organisms isolated in nosocomial infections
is  higher,  while  susceptibility  among  these  strains  is
lower  compared  to  community-acquired  infections
[14]. 
TP is less common and is defined as a severe or re-
current  or  persistent  IaI  after  apparently  successful
and adequate surgical source control of sP [12]. TP is
always  a  nosocomial  infection,  typically  associated
with high morbidity and mortality due to prolonged
systemic  inflammation,  systemic  inflammatory  re-
sponse syndrome, sepsis, severe sepsis or septic shock
[15, 16]. While the mortality of sP is less than 25 %,
mortality for patients with TP is higher than 50 % [8,
17, 18]. although the reasons for the development of
TP are not completely understood, the high mortality
in TP may reflect its association with more virulent
species. figure 1 illustrates the infection source of pa-
tients who developed TP after successful treatment of
sP (fig. 1, causes for sP and TP in surgical ICu pa-
tients) [18].
TyPE of InfECTIon and ModE of
aCquIsITIon IndICaTEs PaTHogEns
Primary peritonitis is usually a mono-microbial infec-
tion with gram-positive Cocci or Enterobacteriaceae.
The  etiology  implies  a  conservative  management,
since primary peritonitis occurs spontaneously without
perforation of a hollow viscus [19].
The species in sP and TP most frequently represent
mixtures of gram-positive and gram-negative aerobes
and anaerobes as well as fungi in certain cases of TP or
in patients with immune suppression [20, 21]. In com-
munity-acquired  sP  facultative  and  obligate  aerobic
gram-negative and gram-positive organisms must be
considered in infections originating from the stomach,
duodenum, biliary system and the small bowel (Table 2,
Micro-organisms in peritonitis) [20, 22]. ulcer perfora-
tions are usually associated with infections with E. coli
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Table 1. forms of peritonitis, according to [12].
Causes of peritonitis Most common bacterial species
Primary bacterial  Peritoneal infection without anatomic barrier disruption;  gram negative Enterobacteriaceae, 
peritonitis most common in patients with cirrhosis or severe immune  streptococcus spp.
dysfunction or early childhood
secondary bacterial  Peritoneal infection with perforation of the gut wall and  Polymicrobial infection with gram- 
peritonitis spillage of bacteria into the peritoneal cavity. This peritonitis  negative Enterobacteriaceae, gram-
may be health care associated or community-acquired positive Enterococci, staphylococci and 
anaerobes
Tertiary peritonitis Persistent or recurrent infection after "adequate" treatment  Polymicrobial infections like in 
of primary or secondary peritonitis; most common in patients  secondary peritonitis, but more likely to 
with severe co-morbidities or compromised immune function involve resistant bacteria
Fig. 1. Causes for sP and TP in surgical ICu pa-
tients,  modified  by  [18].  Infection  source  for  pa-
tients with sP at the index operation, who further
developed TP (n = 15, red bars) and for patients
who did not (sP, n = 54, yellow bars).
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ed sP are E. coli, klebsiella spp. and Enterococci. In
small bowel derived infections gram-negative aerobes
and anaerobes are the most frequent patho  gens. for in-
fections originating from the colon all kinds of differ-
ent aerobes and anaerobes must be considered.
The microbial flora encountered in health care as-
sociated  IaIs  and  TP  includes  the  same  species  as
community-acquired sP with a shift towards oppor-
tunistic, nosocomial facultative pathogens and fungi.
frequent isolates include Enterobacteriaceae with ex-
tended  spectrum  b-lactamase  (Esbl),  Pseudomonas
aeruginosa,  Enterobacter  spp.,  Enterococci,  Methi-
cillin resistant staphylococcus aureus (MRsa), acine-
tobacter  spp.,  Morganella  morganii,  stenotropho  -
monas, coagulase-negative staphylococci and different
forms of Candida. Compared to community-acquired
peritonitis the amount of micro-organisms with resis-
tance mechanisms is higher among these species (fig.
2, germs in sP and TP) [18].
REsIsTanT gERMs
one reason for the progressive amount of antibiotic
resistance among bacteria is the inadequate and inap-
propriate use of antibiotics, as well as an increasing
number of patients with severe co-morbidities. Today,
patients often have a history of previous hospitalisa-
tion and broad-spectrum antibiotic exposure with se-
lection of resistant pathogens [23]. Therefore, the rate
of resistant micro-organisms in patients with hospital
acquired sP ranges between 37 % and 70 % [24]. sev-
eral risk factors for infections with MdR germs have
been identified (Table 3, risk factors for multi-drug re-
sistance) [25-28].
at  the  end  of  the  20th century  most  resistant
species were found among gram-positive bacteria, in-
cluding MRsa and Vancomycin resistant Enterococci
(VRE). In the last decade a shift towards a higher fre-
quency of resistant gram-negative bacteria occurred,
especially among Enterobacteriaceae producing Esbl
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Table 2. Micro-organisms in peritonitis, according to [20].
gastro- biliary small appendicitis abscess liver spleen















bacteroides spp. ￘ (X) XXX ( X ) ￘
Clostridium spp. ￘ (X) X￘X￘￘
anaerobe Cocci ￘￘ (X) ￘ (X) ￘￘
legends:  X = most frequent species;  ￘ = usually not present;   (X) = rarely present
Fig. 2. germs in sP and TP, modified by [18]. Mi-
crobiological  isolates  in  TP  (n  =  11,  red  bars), 
vs. sP (n = 54, yellow bars). The microbial isolates
of TP were obtained from the re-laparotomy that
was diagnostic for TP. Isolates of sP were obtained
at  the  index  operation.  The  rate  of  Enterococcus
and Candida was significantly higher in TP vs. sP
(*p ≤ 0.05).
3 Uhl##_Umbruchvorlage  23.11.10  11:53  Seite 527[29]. figure 3 illustrates the development of resistant
species in a surgical ICu (fig. 3, surgical ICu resis-
tance development).
a high prevalence for MRsa infections is observed
in skin and soft structure infections, as well as in post-
operative wound infections, while sepsis secondary to
MRsa  is  most  frequent  in  pneumonia  and  primary
bacteremia [30-32]. although less common in cIaIs,
infections  with  MRsa  should  be  considered  in  pa-
tients colonized with MRsa, hospital-acquired sP or
TP or if risk other factors are present [26, 33].
Enterobacteriaceae are the most frequent isolates in
cIaI  and  usually  represent  susceptible  micro-organ-
isms. Prior antibiotic therapy affects the development
of  Esbl,  which  is  responsible  for  MdR,  especially
among klebsiella spp., E. coli and Proteus spp. [29,
34, 35].
Enterococci are frequently isolated in patients with
cIaIs. The need for specific therapy against Entero-
cocci in sP has been discussed controversially, but iso-
lation in ICu patients with health care associated sP
or  TP  should  always  imply  antibiotic  treatment  ac-
cording to resistance analyses [36-40].
Pseudomonas aeruginosa is a common pathogen in
pneumonia and in ICus, but has also been frequently
isolated  in  patients  with  appendicitis  and  peritoneal
dialysis [4, 41, 42]. although less frequent, the gram-
negative species stenotrophomonas maltophilia, Mor-
ganella morganii and acinetobacter spp. are responsi-
ble for a substantial part of MdR isolates in cIaIs
[43].
Infections with fungi are less common in communi-
ty-acquired infections, but should always be suspected
in patients with immunodeficiency and prolonged an-
tibacterial exposure [44]. 
RIsk faCToR analysEs
Infections with MdR pathogens are associated with a
higher rate of treatment failure and mortality, but sev-
eral  other  factors  affect  patients’  outcome  (Table  4,
Risk factors for treatment failure or death) [9, 14, 20,
45, 46]. The only risk factor that is not based on pa-
tients’ physiologic constitution is an unsuccessful op-
eration. Thus, the inability to achieve adequate source
control is predictive of mortality [2, 45, 47, 48]. There-
fore, the fundamental basis in the treatment of cIaIs
remains  a  successful  operation,  while  intensive  care
management  and  antibiotic  therapy  are  essential  for
post-operative stabilisation and final outcome of the
individual patient.
The goal of patient adapted individual risk stratifi-
cation should be to select a suitable antibiotic therapy
to avoid the dilemma to be affronted with resistant mi-
cro-organisms after the return of the results from the
microbiology.  Therefore,  assuming  the  patients  risk
for treatment failure is mandatory to optimise the indi-
vidual initial treatment plan.
anTIbIoTIC TREaTMEnT oPTIons
for the antibiotic therapy of cIaIs a broad coverage
against  gram-negative  and  gram-positive  species  is
generally  recommended,  but  several  treatment  regi-
mens lack activity against MdR bacteria. new antibi-
otics, with a narrower spectrum with special activity
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Table 3. Risk factors for MdR, modified by [24-27]. 
Risk factors for multi drug resistance
- High aPaCHE II score
- longer preoperative hospitalisation
- Health care associated peritonitis
- Prior antibiotic treatment
- longer postoperative antibiotic treatment
- Postoperative changes in antibiotic treatment
- longer postoperative hospitalisation
Table 4. Risk factors for treatment failure or death, modified
by [9 20].
Independent risk factors for treatment failure or death in pa-
tients with cIaIs
- High aPaCHE II score
- advanced age
- Malnutrition (Hypoalbuminemia, Hypocholesterolemia)
- Preoperative organ impairement (liver disease, Cardiovas-
cular disease, Renal disease)
- Malignancy
- Corticosteroid therapy (status post transplantation)
- unsuccesful operation
Fig. 3. surgical ICu resistance development.
Percentage of resistant pathogens among iso-
lates. The blue line indicates the increasing
rate of Esbl producing E. coli (blue bars),
while the rate of Esbl producing klebsiella
pneumonia (green bars) and MRsa (orange
bars)  remains  stable.  (own  data,  surgical
ICu,  st.  Josef  Hospital  bochum;  depart-
ment  for  Medical  Microbiology,  university
of bochum).
3 Uhl##_Umbruchvorlage  23.11.10  11:53  Seite 528against MRsa and VRE have been developed, includ-
ing quinupristin, daptomycin and oxazolidinones [49-
51]. While these drugs offer a new opportunity in the
treatment of infections with these difficult to treat or-
ganisms, they have no activity against gram-negative
bacteria. but especially among gram-negative bacteria
the  amount  of  resistant  micro-organisms  producing
Esbl increases constantly, while the rate of infections
with MRsa remains stable (fig. 3, surgical ICu resis-
tance development).
new drugs with activity against gram-positive and
gram-negative resistant germs with special coverage
of Esbl include tigecycline and 4th generation b-lac-
tam  antibiotics  [52-55].  both  derivates  have  broad
spectrum activity against most pathogens commonly
associated with cIaIs, but they do not have a reliable
activity against pseudomonas aeruginosa [56, 57]. 
although all these novelties offer an alternative in
the  presence  of  MdR  species,  each  derivate  has  a
weak point and no compound is able to cover all resis-
tant pathogens (Table 5; antimicrobial agents against
MdR  pathogens)  [50,  58,  59].  In  high  risk  patients
with nosocomial cIaIs the empiric antimicrobial ther-
apy should therefore be selected after consideration of
the likelihood of difficult-to-treat isolates [60].
The only derivates with broad coverage against the
expected flora in sP are Carbapenems, b-lactam an-
tibiotics and tigecycline, since they provide coverage
against  both,  gram-negative  and  gram-positive
species. none of the new derivates with special activi-
ty  against  infections  with  MRsa  and  VRE  (dapto-
mycin and linezolid) covers Esbl, while Enterobacte-
riaceae with Esbl can be treated with ampicillin/sul-
bactam or Piperacillin/Tazobac. Carbapenems and 4th
generation b-lactam antibiotics have no reliable activi-
ty against VRE and MRsa. The only derivate covering
MRsa, VRE and Esbl is tigecycline. The weak point
of  tigecycline  is  the  lacking  activity  against  Pseudo  -
monas aeruginosa, while treatment with Carbapenems
and Piperacillin/sulbactam is effective against Pseudo  -
monas aeruginosa.
TREaTMEnT RECoMMEndaTIon
guidelines aimed at simplifying the antibiotic choice
according to the severity of illness, but in fact most
guidelines do not consider that there is a vast diversity
of differently acting antibiotics [9, 61]. Most antibi-
otics are effective in preventing post-operative compli-
cations following peritonitis, but there is no evidence
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Table 5. antimicrobial agents against MdR pathogens, modified by [49].
MRsa VRE Esbl acinetobacter Pseudomonas aeruginosa
ampicilin/sulbactam ￘￘X￘ ￘
Piperacillin/sulbactam ￘￘X (X) X
glycopeptides (Vancomycin) (X) ￘￘￘ ￘
streptogramins (quinupristin) XX￘￘ ￘
lipopeptides (daptomycin) XX￘￘ ￘
oxazolidinones (linezolid) XX￘￘ ￘
￟-lactams (Ceftobiprole) X (X) XX ￘
Carbapenemes (doripenem) (X) (X) X (X) X
glycylcycline (Tigecycline) XXX (X) ￘
quinolones ￘￘ (X) (X) (X)
legends:  X = effective;  ￘ = not effective;  (X) = partial activity




low risk (localised peritonitis) ampicillin/sulbactam 2nd generation Cephalosporin + Metronidazol
Carbapenem 3rd generation Cephalosporin + Metronidazol
low risk (diffuse peritonitis) ampicillin/sulbactam 2nd generation fluorochinolon + Metronidazol




High risk Piperacillin/Tazobactam 4th generation Cephalosporin + Metronidazol
Carbapenem (group 1/2)
Tigecyclin
Tertiary peritonitis according to resistance from  antifungal therapy in high risk patients
microbiology
3 Uhl##_Umbruchvorlage  23.11.10  11:53  Seite 529to  support  that  one  regimen  is  superior  to  another.
Controversially, regularly changes between the differ-
ent compounds according to the hospital specific epi-
demiology are essential to avoid the development of
resistant germs [62]. The initial empiric antibiotic ther-
apy should be initiated immediately. any delay of ap-
propriate antibiotic treatment increases the probability
of mortality [63-65].
low risk patients with community-acquired sP still
represent the largest group of patients with cIaIs. ac-
cording to the intra-operative findings these patients
should receive “narrow spectrum” agents, e.g. ampi-
cillin/sulbactam or a 3rd generation cephalosporines/
fluorochinolones  and  metronidazol  for  one  or  two
days, if the peritonitis is localized and source control
is  assured.  When  peritonitis  is  diffuse,  piperacillin/
tazobactam,  3rd generation  cephalo  sporines/fluoro  -
chinolones and metronidazol, 4th generation cephalo  -
sporines, a carbapenem or tigecycline should be admit-
ted for 5 to 7 days.
In high risk patients and health care associated peri-
tonitis with a higher suspicion of resistant pathogens,
an  antibiotic  therapy  of  10  to  14  days  with  e.g.
piperacillin/tazobactam,  a  4th generation  cephalo  -
sporin and metronidazol, a carbapenem or tigecycline
is recommended.
In TP the antibiotic choice should be based on mi-
crobial  resistance  analysis  with  inclusion  of  candida
spp. (Table 6; antibiotic treatment recommendations)
[9, 66].
suMMaRy and ConClusIons
In ICu patients the augmenting rate of infections with
resistant bacteria and fungi is a serious problem. In ad-
dition  to  the  control  of  vital  parameters  and  organ
function during ICu stay, the interpretation of resis-
tance analyses from the microbiology is getting more
important than it was in the past. To assure patients’
survival after a successful operation surgeons and in-
tensive care physicians must be aware of the diversity
of resistant bacterial species and fungi to choose the
best antimicrobial agent out of the different classes of
antibiotics. a major concern in the future will be that
physicians will be confronted with an increasing rate
of resistant micro-organisms with a decreasing num-
ber of new antibiotic agents.
at  the  moment  the  two  principles  surgical  treat-
ment and intensive care medicine do not need a sub-
stantial change. However the third part in the treat-
ment of sP, the use of antibiotics, has to be improved.
since the rate of resistant bacteria in sP is 30 % - 40
%, physicians should use the vast diversity of differ-
ently acting antibiotics to optimise the therapy of pa-
tients with sP [14]. Therefore, the initial treatment of
patients at risk for infections with MdR germs should
include a broad spectrum antibiotic, covering the most
frequent resistant bacteria in sP.
Tertiary peritonitis still is a major problem in ICu
patients and is associated with unsatisfactory too high
morbidity and mortality. Patients at risk for the devel-
opment of TP have a high Mannheim peritonitis index
at the index operation and higher saPs II scores dur-
ing ICu stay [18]. The treatment strategy for patients
with TP consists in antibiotic and antifungal therapy in
accordance to the resistance analyses from the micro-
biology.
The best description for the antibiotic treatment in
the  future  has  been  summarized  by  the  “Tarragona
strategy” (Table 7, “Tarragona strategy”) [67]. The ini-
tial empiric antibiotic therapy should be calculated ac-
cording to the individual patients’ risk factors, with re-
spect to the hospital specific surveillance data. The an-
tibiotic choice should be selected out of the vast di-
versity of differently acting antibiotic agents to reduce
the selection pressure.
The “Tarragona strategy” in detail:
Hit hard and early. The initial therapy should include
high doses of broad spectrum antibiotics, even if the
costs are expensive. Initial therapy should be initiated
as soon as possible.
Look at your patient. In patients with community-ac-
quired secondary peritonitis antibiotic therapy should
cover  Enterobacteriaceae  and  anaerobes.  In  patients
with post-operative sP a shift towards more resistant
species  has  to  be  expected  including  gram-negative
and gram- positive species with MdR (Esbl, VRE,
MRsa).  The  highest  risk  for  infections  with  MdR
pathogens exists in patients with serious co-morbidi-
ties, a recent surgical history or prior broad spectrum
antibiotic  therapy.  Therefore,  the  choice  of  cheaper
antibiotics should be reserved for “healthy” patients
without serious co-morbidities.
Listen to your hospital. antibiotic treatment modalities
need a regular update according to the hospital specif-
ic  surveillance  data.  use  broad  spectrum  antibiotics
with wide coverage.
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Table 7. “Tarragona strategy”, according to [66].
Tarragona strategy
look at your patient The choice for a certain antibiotic treatment should be based on individual patients' risk factors
listen to your hospital knowledge of the actual hospital specific surveillance data is essential for the antibiotic choice
Hit hard and fast The therapy should be initiated immediately and be broad enough to reach the vast majority of likely
pathogens
get to the point select antibiotics with pharmacokinetic and -dynamic properties to reach effective concentration at
the side of infection
focus, focus, focus Re-evaluation of the initial therapy after 3 days, depending on the results from the microbiology, 
providing the option of de-escalation to reduce selection pressure and costs
3 Uhl##_Umbruchvorlage  23.11.10  11:53  Seite 530Focus, focus, focus. de-escalation is indicated in stable
patients in accordance to the results from the microbi-
ology to avoid prolonged antibiotic exposure. use the
whole diversity of differently acting antibiotics to re-
duce the selection pressure among pathogens.
successful treatment of cIaIs is based on the three
important columns: focus elimination, intensive care
management and antibiotic therapy. Resistance analy-
ses  of  microbiological  culture  results  became  more
important, since the rate of MdR micro-organisms in-
creased rapidly. Intensive care physicians and surgeons
must be aware of the diversity of different antibiotic
classes to choose an appropriate initial therapy, based
on patients’ risk factors and hospital specific resistance
rates. Immediate and appropriate application of anti  -
microbial agents is mandatory to avoid treatment fail-
ure and the development of new resistance. further
investigation from the pharmaceutical industry for the
development of new antibiotics is essential to assure
effective  treatment  options  in  the  future.  otherwise
we will end up in an a-antibiotic time.
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